Close Menu

NEW YORK (GenomeWeb) – Biocept announced today that it has inked an agreement with Blue Cross Blue Shield of Illinois which gives members access to Biocept's menu of circulating tumor cell and circulating tumor DNA tests. 

According to Biocept, the addition of BCBS IL's more than 8 million members raises the number of patients with health insurance access to Biocept's liquid biopsy assays to approximately 133 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.